Sjoerd S. H. Van Der Burg

Sjoerd S. H. Van Der Burg's AcademicInfluence.com Rankings

Biology

#13526

World Rank

#17075

Historical Rank

Immunology

#939

World Rank

#963

Historical Rank

biology Degrees

Download Badge

Biology

Sjoerd S. H. Van Der Burg's Degrees

Masters Biomedical Sciences Leiden University

Why Is Sjoerd S. H. Van Der Burg Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Sjoerd S. H. Van Der Burg's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. (2009) (987)
Established Human Papillomavirus Type 16-Expressing Tumors Are Effectively Eradicated Following Vaccination with Long Peptides1 (2002) (454)
Identification and manipulation of tumor associated macrophages in human cancers (2011) (429)
Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. (1996) (416)
High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. (2007) (385)
Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine (2008) (380)
Classification of current anticancer immunotherapies (2014) (357)
M2 Macrophages Induced by Prostaglandin E2 and IL-6 from Cervical Carcinoma Are Switched to Activated M1 Macrophages by CD4+ Th1 Cells (2011) (329)
Anti–CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response (2014) (319)
Human Papillomavirus Type 16-Positive Cervical Cancer Is Associated with Impaired CD4+ T-Cell Immunity against Early Antigens E2 and E6 (2004) (316)
Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity (2008) (310)
In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild‐type p53 (1993) (296)
Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16–Related Cancer: A Phase 2 Clinical Trial (2019) (296)
Therapeutic cancer vaccines (2021) (262)
Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment. (2013) (255)
Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses (2010) (245)
Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter. (2003) (238)
CD8+ CTL Priming by Exact Peptide Epitopes in Incomplete Freund’s Adjuvant Induces a Vanishing CTL Response, whereas Long Peptides Induce Sustained CTL Reactivity1 (2007) (235)
Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+ T-Cell Infiltration and Survival of Patients with Cervical Carcinoma (2009) (228)
Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens (2007) (223)
Identification of peptide sequences that potentially trigger HLA‐A2.1‐restricted cytotoxic T lymphocytes (1993) (216)
Human Leukocyte Antigen Class I, MHC Class I Chain-Related Molecule A, and CD8+/Regulatory T-Cell Ratio: Which Variable Determines Survival of Cervical Cancer Patients? (2008) (215)
CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses. (2015) (214)
Therapeutic cancer vaccines. (2010) (200)
Response definition criteria for ELISPOT assays revisited (2010) (195)
Strategies for immunotherapy of cancer. (2000) (184)
Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. (2003) (182)
Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16‐induced tumors (1995) (179)
Prognostic Value of Tumor-Infiltrating Dendritic Cells in Colorectal Cancer: Role of Maturation Status and Intratumoral Localization (2005) (177)
Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. (2002) (176)
Distinct Uptake Mechanisms but Similar Intracellular Processing of Two Different Toll-like Receptor Ligand-Peptide Conjugates in Dendritic Cells* (2007) (175)
HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8+ T lymphocytes (2011) (171)
Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. (2002) (171)
Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study (2016) (168)
Natural T‐helper immunity against human papillomavirus type 16 (hpv16) e7–derived peptide epitopes in patients with hpv16‐positive cervical lesions: Identification of 3 human leukocyte antigen class ii–restricted epitopes (2001) (161)
HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial (2013) (160)
Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens. (2001) (157)
Molecular Mimicry of Human Cytochrome P450 by Hepatitis C Virus at the Level of Cytotoxic T Cell Recognition (1999) (157)
Induction of p53-Specific Immunity by a p53 Synthetic Long Peptide Vaccine in Patients Treated for Metastatic Colorectal Cancer (2009) (157)
Therapy of human papillomavirus-related disease. (2012) (155)
Human Papillomavirus (HPV) Upregulates the Cellular Deubiquitinase UCHL1 to Suppress the Keratinocyte's Innate Immune Response (2013) (154)
Defining the critical hurdles in cancer immunotherapy (2011) (152)
Human Papillomavirus Deregulates the Response of a Cellular Network Comprising of Chemotactic and Proinflammatory Genes (2011) (152)
Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry (2015) (149)
Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T‐cell activation (2013) (149)
Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses (2016) (147)
The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays (2007) (147)
Antibodies against p53 are associated with poor prognosis of colorectal cancer. (1995) (145)
Spontaneous tumor rejection by cbl-b–deficient CD8+ T cells (2007) (135)
T cell assays and MIATA: the essential minimum for maximum impact. (2012) (134)
Immunological Responses in Women with Human Papillomavirus Type 16 (HPV-16)-Associated Anogenital Intraepithelial Neoplasia Induced by Heterologous Prime-Boost HPV-16 Oncogene Vaccination (2004) (134)
Design and development of synthetic peptide vaccines: past, present and future (2007) (131)
Therapeutic vaccination against human papilloma virus induced malignancies. (2011) (130)
Monalizumab: inhibiting the novel immune checkpoint NKG2A (2019) (129)
Immunization with a P53 synthetic long peptide vaccine induces P53‐specific immune responses in ovarian cancer patients, a phase II trial (2009) (126)
A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer. (2015) (121)
Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response (2016) (119)
Consensus nomenclature for CD8+ T cell phenotypes in cancer (2015) (118)
Therapeutic vaccination with papillomavirus E6 and E7 long peptides results in the control of both established virus-induced lesions and latently infected sites in a pre-clinical cottontail rabbit papillomavirus model. (2005) (118)
Characterization of HLA-B57-restricted human immunodeficiency virus type 1 Gag- and RT-specific cytotoxic T lymphocyte responses. (1998) (114)
Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes (2002) (113)
Tumor‐infiltrating CD14‐positive myeloid cells and CD8‐positive T‐cells prolong survival in patients with cervical carcinoma (2013) (112)
Anti‐inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor‐treated gastrointestinal stromal tumors (2010) (109)
Intratumoral HPV16-Specific T Cells Constitute a Type I–Oriented Tumor Microenvironment to Improve Survival in HPV16-Driven Oropharyngeal Cancer (2017) (108)
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers (2011) (108)
A prospective study on the natural course of low‐grade squamous intraepithelial lesions and the presence of HPV16 E2‐, E6‐ and E7‐specific T‐cell responses (2010) (104)
Design and evaluation of antigen-specific vaccination strategies against cancer. (2000) (104)
Importance of CD4(+) T helper cell responses in tumor immunity. (2000) (103)
Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy. (2006) (103)
Systemic and local human papillomavirus 16‐specific T‐cell immunity in patients with head and neck cancer (2012) (103)
p53, a potential target for tumor-directed T cells. (1994) (102)
An HLA class I peptide-binding assay based on competition for binding to class I molecules on intact human B cells. Identification of conserved HIV-1 polymerase peptides binding to HLA-A*0301. (1995) (99)
Tumor Eradication by Cisplatin Is Sustained by CD80/86-Mediated Costimulation of CD8+ T Cells. (2016) (98)
Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine. (2002) (97)
Analogues of CTL epitopes with improved MHC class‐I binding capacity elicit anti‐melanoma CTL recognizing the wild‐type epitope (1997) (96)
Activation of Tumor-Promoting Type 2 Macrophages by EGFR-Targeting Antibody Cetuximab (2011) (95)
Peptide‐pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA‐A*0201‐binding peptides from the Melan‐A/MART‐1 self antigen (1996) (94)
The nonpolymorphic MHC Qa-1b mediates CD8+ T cell surveillance of antigen-processing defects (2010) (91)
Genetic variation of antigen processing machinery components and association with cervical carcinoma (2007) (91)
Harmonization of Immune Biomarker Assays for Clinical Studies (2011) (91)
Tumor-specific regulatory T cells in cancer patients. (2008) (88)
Features of Effective T Cell-Inducing Vaccines against Chronic Viral Infections (2018) (88)
Vaccination for treatment and prevention of cancer in animal models. (2006) (87)
Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA‐DQ and –DP as a restriction element (2008) (87)
Impact of (chemo)radiotherapy on immune cell composition and function in cervical cancer patients (2016) (82)
A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions (2012) (82)
Alternative peptide repertoire of HLA-E reveals a binding motif that is strikingly similar to HLA-A2. (2013) (80)
Detection of Human Papillomavirus (HPV) 16-Specific CD4+ T-cell Immunity in Patients with Persistent HPV16-Induced Vulvar Intraepithelial Neoplasia in Relation to Clinical Impact of Imiquimod Treatment (2005) (80)
Vaccine-Induced Tumor Necrosis Factor–Producing T Cells Synergize with Cisplatin to Promote Tumor Cell Death (2014) (79)
Genetic evolution of uveal melanoma guides the development of an inflammatory microenvironment (2017) (79)
An unexpectedly large polyclonal repertoire of HPV-specific T cells is poised for action in patients with cervical cancer. (2010) (77)
Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+ and CD8+ T cells in combination with low-dose interferon-alpha (2011) (75)
Bronchiolitis obliterans organizing pneumonia and rheumatoid arthritis. (1991) (74)
Detection of human papillomavirus type 18 E6 and E7‐specific CD4+ T‐helper 1 immunity in relation to health versus disease (2006) (73)
Competition-based cellular peptide binding assays for 13 prevalent HLA class I alleles using fluorescein-labeled synthetic peptides. (2003) (72)
Therapeutic Peptide Vaccine-Induced CD8 T Cells Strongly Modulate Intratumoral Macrophages Required for Tumor Regression (2015) (72)
Identification of three non‐VNTR MUC1‐derived HLA‐A*0201‐restricted T‐cell epitopes that induce protective anti‐tumor immunity in HLA‐A2/Kb‐transgenic mice (2001) (72)
Identification of HLA‐A*0201‐restricted CTL epitopes encoded by the tumor‐specific MAGE‐2 gene product (1997) (71)
Human immunodeficiency virus and human papilloma virus - why HPV-induced lesions do not spontaneously resolve and why therapeutic vaccination can be successful (2009) (69)
Potentiation of a p53‐SLP vaccine by cyclophosphamide in ovarian cancer: A single‐arm phase II study (2012) (69)
Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond (2010) (68)
Detection and Functional Analysis of CD8+ T Cells Specific for PRAME: a Target for T-Cell Therapy (2006) (68)
Balancing between antitumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen. (2008) (68)
Toward the harmonization of immune monitoring in clinical trials: Quo vadis? (2007) (67)
p53: A Potential Target Antigen for Immunotherapy of Cancer (2000) (66)
CXCR7 expression is associated with disease-free and disease-specific survival in cervical cancer patients (2012) (65)
A beneficial tumor microenvironment in oropharyngeal squamous cell carcinoma is characterized by a high T cell and low IL-17+ cell frequency (2016) (65)
Long lasting p53‐specific T cell memory responses in the absence of anti‐p53 antibodies in patients with resected primary colorectal cancer (2001) (64)
Strong vaccine responses during chemotherapy are associated with prolonged cancer survival (2020) (63)
The need for improvement of the treatment of advanced and metastatic cervical cancer, the rationale for combined chemo-immunotherapy. (2014) (63)
Characterization of cytotoxic T lymphocyte epitopes of a self-protein, p53, and a non-self-protein, influenza matrix: relationship between major histocompatibility complex peptide binding affinity and immune responsiveness to peptides. (1993) (62)
The interferon-related developmental regulator 1 is used by human papillomavirus to suppress NFκB activation (2015) (62)
The positive prognostic effect of stromal CD8+ tumor-infiltrating T cells is restrained by the expression of HLA-E in non-small cell lung carcinoma (2015) (62)
Antitumor efficacy of wild-type p53-specific CD4(+) T-helper cells. (2002) (61)
The NKG2A–HLA-E Axis as a Novel Checkpoint in the Tumor Microenvironment (2020) (59)
Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple, and immunogenic (2008) (58)
Tumor mutational load, CD8+ T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients (2020) (58)
Chirality of TLR-2 ligand Pam3CysSK4 in fully synthetic peptide conjugates critically influences the induction of specific CD8+ T-cells. (2009) (57)
Identification of potential HLA-A *0201 restricted CTL epitopes derived from the epithelial cell adhesion molecule (Ep-CAM) and the carcinoembryonic antigen (CEA). (1997) (56)
Multiple CD4 and CD8 T-cell activation parameters predict vaccine efficacy in vivo mediated by individual DC-activating agonists. (2007) (56)
Interleukin-6/interleukin-6 receptor pathway as a new therapy target in epithelial ovarian cancer. (2012) (56)
CD39 Identifies the CD4+ Tumor-Specific T-cell Population in Human Cancer (2020) (55)
TAP-independent self-peptides enhance T cell recognition of immune-escaped tumors. (2016) (55)
Distinct regulation and impact of type 1 T‐cell immunity against HPV16 L1, E2 and E6 antigens during HPV16‐induced cervical infection and neoplasia (2006) (55)
A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer (2015) (54)
Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer. (2013) (53)
Identification of non-mutated neoantigens presented by TAP-deficient tumors (2018) (53)
Self-tolerance does not restrict the CD4+ T-helper response against the p53 tumor antigen. (2008) (53)
The detection of circulating human papillomavirus‐specific T cells is associated with improved survival of patients with deeply infiltrating tumors (2011) (52)
Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy (2019) (51)
Immunotherapy for persistent viral infections and associated disease. (2011) (51)
Metabolic stress in cancer cells induces immune escape through a PI3K-dependent blockade of IFNγ receptor signaling (2019) (51)
Addition of interferon‐α to the p53‐SLP® vaccine results in increased production of interferon‐γ in vaccinated colorectal cancer patients: A phase I/II clinical trial (2013) (51)
Induction of a primary human cytotoxic T‐lymphocyte response against a novel conserved epitope in a functional sequence of HIV‐1 reverse transcriptase (1995) (50)
Peptide vaccination after T-cell transfer causes massive clonal expansion, tumor eradication, and manageable cytokine storm. (2010) (50)
Identification of a conserved universal Th epitope in HIV-1 reverse transcriptase that is processed and presented to HIV-specific CD4+ T cells by at least four unrelated HLA-DR molecules. (1999) (50)
Long‐term clinical and immunological effects of p53‐SLP® vaccine in patients with ovarian cancer (2012) (49)
Inhibition of CSF-1R Supports T-Cell Mediated Melanoma Therapy (2014) (49)
Immunotherapeutic Potential of TGF-β Inhibition and Oncolytic Viruses. (2020) (49)
Performance of serum-supplemented and serum-free media in IFNγ Elispot Assays for human T cells (2009) (49)
Targeting of the MAPK and AKT pathways in conjunctival melanoma shows potential synergy (2016) (47)
Surgery followed by Persistence of High-Grade Squamous Intraepithelial Lesions Is Associated with the Induction of a Dysfunctional HPV16-Specific T-Cell Response (2008) (46)
Harmonization of the intracellular cytokine staining assay (2012) (44)
Skin reactions to human papillomavirus (HPV) 16 specific antigens intradermally injected in healthy subjects and patients with cervical neoplasia (2008) (43)
Rationally combining immunotherapies to improve efficacy of immune checkpoint blockade in solid tumors. (2017) (43)
The nonpolymorphic MHC Qa-1b mediates CD8+ T cell surveillance of antigen-processing defects (2010) (43)
Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancer (2020) (43)
Uveal Versus Cutaneous Melanoma; Same Origin, Very Distinct Tumor Types (2019) (43)
Heterogeneity revealed by integrated genomic analysis uncovers a molecular switch in malignant uveal melanoma (2015) (43)
The Anatomical Location Shapes the Immune Infiltrate in Tumors of Same Etiology and Affects Survival (2018) (42)
Clinical Characteristics Associated With Development of Recurrence and Progression in Usual-Type Vulvar Intraepithelial Neoplasia (2013) (42)
Correlates of immune and clinical activity of novel cancer vaccines. (2018) (41)
TLR2 ligand-synthetic long peptide conjugates effectively stimulate tumor-draining lymph node T cells of cervical cancer patients (2016) (41)
Intradermal Delivery of TLR Agonists in a Human Explant Skin Model: Preferential Activation of Migratory Dendritic Cells by Polyribosinic-Polyribocytidylic Acid and Peptidoglycans (2013) (41)
CD8+ T Cell Responses against TAP-Inhibited Cells Are Readily Detected in the Human Population (2010) (40)
Intraepithelial macrophage infiltration is related to a high number of regulatory T cells and promotes a progressive course of HPV‐induced vulvar neoplasia (2015) (40)
Immunological and Clinical Effects of Vaccines Targeting p53-Overexpressing Malignancies (2011) (40)
Targeting of the Cancer-Associated Fibroblast—T-Cell Axis in Solid Malignancies (2019) (40)
P53‐specific T cell responses in patients with malignant and benign ovarian tumors: Implications for p53 based immunotherapy (2007) (39)
Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma* (2018) (38)
Identification, Isolation, and Culture of HLA-A2-Specific B Lymphocytes Using MHC Class I Tetramers 1 (2003) (38)
Vulvar cancer subclassification by HPV and p53 status results in three clinically distinct subtypes. (2020) (38)
Prediction of the immunogenic potential of frameshift‐mutated antigens in microsatellite instable cancer (2008) (37)
High-Risk Human Papillomavirus Targets Crossroads in Immune Signaling (2015) (37)
Magnitude and polarization of P53‐specific T‐helper immunity in connection to leukocyte infiltration of colorectal tumors (2003) (37)
Alterations in classical and nonclassical HLA expression in recurrent and progressive HPV‐induced usual vulvar intraepithelial neoplasia and implications for immunotherapy (2014) (36)
HIV-1 reverse transcriptase-specific CTL against conserved epitopes do not protect against progression to AIDS. (1997) (35)
New Role of Signal Peptide Peptidase To Liberate C-Terminal Peptides for MHC Class I Presentation (2013) (34)
CD4+ T Cell and NK Cell Interplay Key to Regression of MHC Class Ilow Tumors upon TLR7/8 Agonist Therapy (2017) (33)
Generating HPV specific T helper cells for the treatment of HPV induced malignancies using TCR gene transfer (2011) (33)
FOXP3 immunohistochemistry on formalin-fixed paraffin-embedded tissue: poor correlation between different antibodies (2008) (32)
Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4 (2019) (32)
Cytotoxic T lymphocytes in HIV-1 infection: a killing paradox? (1998) (32)
Peptide transporter TAP mediates between competing antigen sources generating distinct surface MHC class I peptide repertoires (2011) (32)
Tumor-infiltrating Cytotoxic T Lymphocytes as Independent Prognostic Factor in Epithelial Ovarian Cancer With Wilms Tumor Protein 1 Overexpression (2011) (31)
The status of HPV16-specific T-cell reactivity in health and disease as a guide to HPV vaccine development. (2002) (30)
Serum is not required for ex vivo IFN-γ ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program (2010) (30)
Rapid enrichment of human papillomavirus (HPV)‐specific polyclonal T cell populations for adoptive immunotherapy of cervical cancer (2005) (30)
Interplay between human papillomaviruses and dendritic cells. (2003) (29)
The use of Epstein-Barr virus-transformed B lymphocyte cell lines in a peptide-reconstitution assay: identification of CEA-related HLA-A*0301-restricted potential cytotoxic T-lymphocyte epitopes. (1995) (29)
Characterization of Antigen-Specific Immune Responses Induced by Canarypox Virus Vaccines1 (2007) (28)
The blood mMDSC to DC ratio is a sensitive and easy to assess independent predictive factor for epithelial ovarian cancer survival (2018) (28)
Digital PCR-Based T-cell Quantification–Assisted Deconvolution of the Microenvironment Reveals that Activated Macrophages Drive Tumor Inflammation in Uveal Melanoma (2018) (27)
Colorectal cancer vaccines in clinical trials (2011) (27)
Expression of coinhibitory receptors on T cells in the microenvironment of usual vulvar intraepithelial neoplasia is related to proinflammatory effector T cells and an increased recurrence‐free survival (2015) (27)
De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute (2016) (27)
Harmonisation of short-term in vitro culture for the expansion of antigen-specific CD8+ T cells with detection by ELISPOT and HLA-multimer staining (2014) (27)
Efficient ex vivo induction of T cells with potent anti-tumor activity by protein antigen encapsulated in nanoparticles (2013) (26)
The importance of correctly timing cancer immunotherapy (2017) (26)
Effective Cooperation of Monoclonal Antibody and Peptide Vaccine for the Treatment of Mouse Melanoma (2013) (26)
Future Challenges in Cancer Resistance to Immunotherapy (2020) (25)
Demarcated thresholds of tumor-specific CD8 T cells elicited by MCMV-based vaccine vectors provide robust correlates of protection (2019) (25)
Serum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocols (2012) (25)
Human Papillomavirus Downregulates the Expression of IFITM1 and RIPK3 to Escape from IFNγ- and TNFα-Mediated Antiproliferative Effects and Necroptosis (2016) (24)
Effect of hypoxic stress on migration and characteristics of monocytes in uveal melanoma. (2014) (24)
Therapeutic vaccines in cancer: moving from immunomonitoring to immunoguiding (2008) (24)
Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model (2020) (24)
Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy (2020) (24)
The simultaneous ex vivo detection of low-frequency antigen-specific CD4+ and CD8+ T-cell responses using overlapping peptide pools (2012) (24)
Circulating human papillomavirus type 16 specific T‐cells are associated with HLA Class I expression on tumor cells, but not related to the amount of viral oncogene transcripts (2007) (23)
Potential use of lymph node-derived HPV-specific T cells for adoptive cell therapy of cervical cancer (2016) (23)
Loss of BAP1 Is Associated with Upregulation of the NFkB Pathway and Increased HLA Class I Expression in Uveal Melanoma (2019) (23)
CD40-Mediated Amplification of Local Immunity by Epithelial Cells Is Impaired by HPV (2014) (22)
Mechanisms of peptide vaccination in mouse models: tolerance, immunity, and hyperreactivity. (2012) (22)
High numbers of activated helper T cells are associated with better clinical outcome in early stage vulvar cancer, irrespective of HPV or p53 status (2019) (22)
Effect of Productive Human Papillomavirus 16 Infection on Global Gene Expression in Cervical Epithelium (2018) (22)
The tumor area occupied by Tbet+ cells in deeply invading cervical cancer predicts clinical outcome (2015) (22)
Human papillomavirus 16 E2-, E6- and E7-specific T-cell responses in children and their mothers who developed incident cervical intraepithelial neoplasia during a 14-year follow-up of the Finnish Family HPV cohort (2014) (22)
EGFR signaling suppresses type 1 cytokine-induced T-cell attracting chemokine secretion in head and neck cancer (2018) (22)
Tbet-positive regulatory T cells accumulate in oropharyngeal cancers with ongoing tumor-specific type 1 T cell responses (2019) (21)
Pre-existing inflammatory immune microenvironment predicts the clinical response of vulvar high-grade squamous intraepithelial lesions to therapeutic HPV16 vaccination (2020) (21)
T cells specific for a TAP-independent self-peptide remain naïve in tumor-bearing mice and are fully exploitable for therapy (2017) (21)
CD163+ cytokine-producing cDC2 stimulate intratumoral type 1 T cell responses in HPV16-induced oropharyngeal cancer (2020) (21)
Long-term Survival and Clinical Benefit from Adoptive T-cell Transfer in Stage IV Melanoma Patients Is Determined by a Four-Parameter Tumor Immune Signature (2017) (21)
T Cells Engaging the Conserved MHC Class Ib Molecule Qa-1b with TAP-Independent Peptides Are Semi-Invariant Lymphocytes (2018) (21)
Synthesis of 2-alkoxy-8-hydroxyadenylpeptides: towards synthetic epitope-based vaccines. (2006) (21)
The development of standard samples with a defined number of antigen-specific T cells to harmonize T cell assays: a proof-of-principle study (2012) (20)
Cryopreservation of MHC Multimers: Recommendations for Quality Assurance in Detection of Antigen Specific T Cells (2014) (20)
2-Azidoalkoxy-7-hydro-8-oxoadenine derivatives as TLR7 agonists inducing dendritic cell maturation. (2009) (20)
Influenza matrix 1‐specific human CD4+FOXP3+ and FOXP3− regulatory T cells can be detected long after viral clearance (2010) (19)
Aqueous Humor Biomarkers Identify Three Prognostic Groups in Uveal Melanoma. (2019) (18)
Chemically synthesized protein as tumour-specific vaccine: immunogenicity and efficacy of synthetic HPV16 E7 in the TC-1 mouse tumour model. (2004) (17)
IDO and galectin-3 hamper the ex vivo generation of clinical grade tumor-specific T cells for adoptive cell therapy in metastatic melanoma (2017) (17)
Control of immune escaped human papilloma virus is regained after therapeutic vaccination. (2017) (17)
Monitoring of the Immune Dysfunction in Cancer Patients (2016) (16)
The Breadth of Synthetic Long Peptide Vaccine-Induced CD8+ T Cell Responses Determines the Efficacy against Mouse Cytomegalovirus Infection (2016) (16)
Human papillomavirus 16-specific cell-mediated immunity in children born to mothers with incident cervical intraepithelial neoplasia (CIN) and to those constantly HPV negative (2015) (16)
The immune microenvironment in vulvar (pre)cancer: review of literature and implications for immunotherapy (2018) (16)
New approaches in vaccine-based immunotherapy for human papillomavirus-induced cancer. (2015) (16)
Affinity, specificity and T‐cell‐receptor diversity of melanoma‐specific CTL generated in vitro against a single tyrosinase epitope (1997) (15)
The presence of human papillomavirus (HPV) in placenta and/or cord blood might result in Th2 polarization (2017) (15)
Treatment failure in patients with HPV 16-induced vulvar intraepithelial neoplasia: understanding different clinical responses to immunotherapy (2012) (14)
The Potential and Challenges of Exploiting the Vast But Dynamic Neoepitope Landscape for Immunotherapy (2017) (14)
Lack of myeloid cell infiltration as an acquired resistance strategy to immunotherapy (2020) (14)
Local and systemic XAGE-1b-specific immunity in patients with lung adenocarcinoma (2015) (13)
Evaluation of immunological cross-reactivity between clade A9 high-risk human papillomavirus types on the basis of E6-Specific CD4+ memory T cell responses. (2010) (13)
Dominant contribution of the proteasome and metalloproteinases to TAP-independent MHC-I peptide repertoire. (2014) (13)
Standard radiotherapy but not chemotherapy impairs systemic immunity in non-small cell lung cancer (2016) (12)
Cell mediated immunity against HPV16 E2, E6 and E7 peptides in women with incident CIN and in constantly HPV-negative women followed-up for 10-years (2015) (12)
Tissue-Specific Gene Expression during Productive Human Papillomavirus 16 Infection of Cervical, Foreskin, and Tonsil Epithelium (2019) (12)
Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma* (2019) (12)
Managing Multi-center Flow Cytometry Data for Immune Monitoring (2014) (12)
Do epitopes derived from autoantigens display low affinity for MHC class I? (1997) (12)
Low-dose interferon-alpha preconditioning and adoptive cell therapy in patients with metastatic melanoma refractory to standard (immune) therapies: a phase I/II study (2020) (11)
The Tumor Microenvironment and Immunotherapy of Oropharyngeal Squamous Cell Carcinoma (2020) (11)
Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy (2019) (11)
Photochemical Internalization Enhanced Vaccination Is Safe, and Gives Promising Cellular Immune Responses to an HPV Peptide-Based Vaccine in a Phase I Clinical Study in Healthy Volunteers (2021) (11)
Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. (2018) (10)
Interleukin‐6‐mediated resistance to immunotherapy is linked to impaired myeloid cell function (2020) (10)
T-regulatory cells in tumour-specific vaccination strategies. (2008) (10)
Long-term HPV-specific immune response after one versus two and three doses of bivalent HPV vaccination in Dutch girls. (2019) (10)
Enforced OX40 Stimulation Empowers Booster Vaccines to Induce Effective CD4+ and CD8+ T Cell Responses against Mouse Cytomegalovirus Infection (2017) (9)
Epitope Selection for HLA-DQ2 Presentation: Implications for Celiac Disease and Viral Defense (2019) (9)
A pre‐existing coordinated inflammatory microenvironment is associated with complete response of vulvar high‐grade squamous intraepithelial lesions to different forms of immunotherapy (2020) (9)
Immunotherapy of cancer through targeting of the p53 tumor antigen. (2002) (9)
Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. (2019) (9)
Tumor-specific T cells support chemokine-driven spatial organization of intratumoral immune microaggregates needed for long survival (2022) (9)
Autologous dendritic cells pulsed with allogeneic tumour cell lysate induce tumour-reactive T-cell responses in patients with pancreatic cancer: A phase I study. (2022) (9)
Enhanced antigen cross-presentation in human colorectal cancer-associated fibroblasts through upregulation of the lysosomal protease cathepsin S (2022) (9)
T-regulatory cells in tumour-specific vaccination strategies (2008) (8)
CD161 expression and regulation defines rapidly responding effector CD4+ T cells associated with improved survival in HPV16-associated tumors (2022) (7)
Immunotherapy of Human Papilloma Virus Induced Disease (2012) (7)
Generation of TCR-Engineered T Cells and Their Use To Control the Performance of T Cell Assays (2015) (7)
NKG2A is a late immune checkpoint on CD8 T cells and marks repeated stimulation and cell division (2021) (7)
Correction: Corrigendum: High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma (2016) (6)
Host genetics and tumor environment determine the functional impact of neutrophils in mouse tumor models (2020) (6)
TEIPP peptides: exploration of unTAPped cancer antigens (2019) (6)
A framework for T cell assays (2015) (6)
Recent progress in peptide vaccination in cancer with a focus on non-small-cell lung cancer (2014) (5)
Cross-presentation of a TAP-independent signal peptide induces CD8 T immunity to escaped cancers but necessitates anchor replacement (2021) (5)
Challenges in neoantigen-directed therapeutics. (2022) (5)
Predictive Biomarkers for Outcomes of Immune Checkpoint Inhibitors (ICIs) in Melanoma: A Systematic Review. (2021) (5)
Primary vulvar squamous cell carcinomas with high T cell infiltration and active immune signaling are potential candidates for neoadjuvant PD-1/PD-L1 immunotherapy (2021) (5)
Melanoma cells can be eliminated by sialylated CD43 × CD3 bispecific T cell engager formats in vitro and in vivo (2020) (5)
IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors (2021) (5)
Differential Expression of CD49a and CD49b Determines Localization and Function of Tumor-Infiltrating CD8+ T Cells (2021) (5)
Antigen size influences the type of glomerular pathology in chronic serum sickness. (1993) (5)
Development of an RNA-based kit for easy generation of TCR-engineered lymphocytes to control T-cell assay performance. (2018) (5)
Interferon‐γ and IL‐5 associated cell‐mediated immune responses to HPV16 E2 and E6 distinguish between persistent oral HPV16 infections and noninfected mucosa (2021) (4)
Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. (2019) (4)
Synergy between chemotherapy and cancer vaccination (2015) (3)
PROTECT: Prospective Phase-II-Trial Evaluating Adaptive Proton Therapy for Cervical Cancer to Reduce the Impact on Morbidity and the Immune System (2021) (3)
Preinduced reovirus-specific T-cell immunity enhances the anticancer efficacy of reovirus therapy (2022) (3)
CD47/SIRPα axis: bridging innate and adaptive immunity (2022) (3)
Detection and functional assessment of regulatory T cells in clinical samples (2014) (2)
Phase I/II study protocol to assess safety and efficacy of adoptive cell therapy with anti-PD-1 plus low-dose pegylated-interferon-alpha in patients with metastatic melanoma refractory to standard of care treatments: the ACTME trial (2020) (2)
Editorial overview: Tumour immunology: What's beyond today's success in tumor immunology. (2016) (2)
Blood-based kinase activity profiling: a potential predictor of response to immune checkpoint inhibition in metastatic cancer (2020) (2)
Tumor-Infiltrating T Cells Can Be Expanded Successfully from Primary Uveal Melanoma after Separation from Their Tumor Environment (2022) (2)
Intradermal vaccination of HPV-16 E6 synthetic peptides conjugated to an optimized Toll-like receptor 2 ligand shows safety and potent T cell immunogenicity in patients with HPV-16 positive (pre-)malignant lesions (2022) (1)
Dataset from a proteomics analysis of tumor antigens shared between an allogenic tumor cell lysate vaccine and pancreatic tumor tissue. (2022) (1)
Actively personalized vaccination trial for newly diagnosed glioblastoma (2018) (1)
Regulatory T Cell Depletion Using a CRISPR Fc-Optimized CD25 Antibody (2022) (1)
Short-Term Fasting Synergizes with Solid Cancer Therapy by Boosting Antitumor Immunity (2022) (1)
IL11: A Specific Repressor of Tumor-Specific CD4+ T Cells (2021) (1)
Safety and tumour-specific immunological responses of combined dendritic cell vaccination and anti-CD40 agonistic antibody treatment for patients with metastatic pancreatic cancer: protocol for a phase I, open-label, single-arm, dose-escalation study (REACtiVe-2 trial) (2022) (1)
The common HLA class I-restricted tumor-infiltrating T cell response in HPV16-induced cancer. (2022) (1)
The presence of human papillomavirus (HPV) in placenta and/or cord blood might result in Th2 polarization (2017) (1)
Human papillomavirus 16 E2-, E6- and E7-specific T-cell responses in children and their mothers who developed incident cervical intraepithelial neoplasia during a 14-year follow-up of the Finnish Family HPV cohort (2014) (1)
p53-specific serum antibodies are not associated with a history of skin carcinoma in renal transplant recipients and immunocompetent individuals. (2005) (1)
Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. (2008) (1)
Induction of a Systemic Immune Response during Use of an Allogenic Leukemia-Derived Dendritic Cell Vaccine in MRD+ AML Patients Correlates with Clinical Response and MRD Conversion (2022) (0)
Generation of TCR-engineered reference cell samples to control T-cell assay performance. (2020) (0)
HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial (2013) (0)
Invasive margin tissue-resident macrophages of high CD163 expression impede responses to T cell-based immunotherapy (2023) (0)
Targeting of cytotoxic T cells against leukemic B cells by bispecific antibody (aCD3 x aCD19) does not distract the T cell from its primary target. (1997) (0)
The identification of patients at high risk for recurrent disease after treatment for early-stage cervical cancer. (2017) (0)
A multigene circulating biomarker to predict the lack of FOLFIRINOX response after a single cycle in patients with pancreatic ductal adenocarcinoma. (2022) (0)
Withdrawal: Identification of tumor antigens among the HLA peptidomes of glioblastoma tumors and plasma. (2019) (0)
163 Immune-based biomarker accurately predicts response to imiquimod immunotherapy in cervical high-grade squamous intraepithelial lesions (2022) (0)
The tumor area occupied by Tbet+ cells in deeply invading cervical cancer predicts clinical outcome (2015) (0)
Editorial: Cancer Prevention: Targeting Premalignant Epithelial Neoplasms in the Era of Cancer Immunotherapy and Vaccines (2022) (0)
Exploration of the Course of the p53 Specific Immune Response During Primary Treatment for Ovarian Cancer (2005) (0)
Human Papillary and Reticular Fibroblasts Show Distinct Functions on Tumor Behavior in 3D-Organotypic Cultures Mimicking Melanoma and HNSCC (2022) (0)
Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma (2019) (0)
Withdrawal: Identification of tumor antigens among the HLA peptidomes of glioblastoma tumors and plasma. (2019) (0)
Immune-based biomarker accurately predicts response to imiquimod immunotherapy in cervical high-grade squamous intraepithelial lesions (2022) (0)
Human papillomavirus 16-specific cell-mediated immunity in children born to mothers with incident cervical intraepithelial neoplasia (CIN) and to those constantly HPV negative (2015) (0)
Characterization of the early cellular immune response induced by HPV vaccines (2022) (0)
CD103 and CD39 coexpression identifies neoantigen-specific cytotoxic T cells in colorectal cancers with low mutation burden (2023) (0)
Neoantigen-specific immunity in low mutation burden colorectal cancers of the consensus molecular subtype 4 (2019) (0)
Withdrawal: Identification of tumor antigens among the HLA peptidomes of glioblastoma tumors and plasma. (2019) (0)
Neoantigen-directed therapeutics in the clinic: where are we? (2023) (0)
Synergy of therapeutic vaccination against HPV16 oncogenic proteins and standard chemotherapeutics (2014) (0)
000293 EXPLORATION OF THE COURSE OF THE P53 SPECIFIC IMMUNE RESPONSE DURING PRIMARY TREATMENT FOR OVARIAN CANCER (2005) (0)
Intertumoral Differences Dictate the Outcome of TGF-β Blockade on the Efficacy of Viro-Immunotherapy (2023) (0)
Cell mediated immunity against HPV16 E2, E6 and E7 peptides in women with incident CIN and in constantly HPV-negative women followed-up for 10-years (2015) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Sjoerd S. H. Van Der Burg?

Sjoerd S. H. Van Der Burg is affiliated with the following schools:

Leiden University